John Sperzel discusses how T2 Biosystems technology is an improvement over the current standard of care for detecting bloodstream infections (BSI) as well as T2’s response to the COVID-19 pandemic. He also outlines T2 Biosystems’ first-quarter earnings for 2021 and the future pipeline of products. Sperzel also shares information about his book, Courage: Powerful Lessons in Leadership, Strength, and the Will to Succeed, as it relates to his personal history as a heart transplant recipient as a sepsis survivor.
John Sperzel shares more details about his history as a transplant recipient and sepsis survivor, and how his journey led him to join T2 Biosystems as President and CEO. In addition to his story, he also discusses the limitations of the current standard of care for sepsis in US hospitals.